piracetam has been researched along with neuropeptide y in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolwig, TG; Hansen, SL; Husum, H; Mathé, AA; Sánchez, C | 1 |
| Foti, S; Gallagher, M; Haberman, RP; Koh, MT; McCown, TJ | 1 |
| Gallagher, M; Koh, MT; Rapp, PR; Spiegel, AM; Vogt, NM | 1 |
| Chen, W; Chen, Y; Ge, Y; Liu, X; Tan, Y | 1 |
4 other study(ies) available for piracetam and neuropeptide y
| Article | Year |
|---|---|
Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling: implications for antiepileptogenic and mood-stabilizing propert
Topics: Affect; Amygdala; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Electroencephalography; Escape Reaction; Gene Expression Regulation; Hippocampus; Kindling, Neurologic; Levetiracetam; Male; Motivation; Neuropeptide Y; Piracetam; Rats; Rats, Wistar; Receptors, Neuropeptide Y; RNA, Messenger | 2004 |
Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment.
Topics: Age Factors; Aging; Animals; Anticonvulsants; CA3 Region, Hippocampal; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Levetiracetam; Male; Maze Learning; Neuropeptide Y; Peptide Fragments; Piracetam; Rats; Rats, Long-Evans; Space Perception; Transduction, Genetic; Valproic Acid | 2010 |
Hilar interneuron vulnerability distinguishes aged rats with memory impairment.
Topics: Aging; Animals; Antigens, Nuclear; Behavior, Animal; CA3 Region, Hippocampal; Cell Count; Cognition; Glutamate Decarboxylase; Hippocampus; Imaging, Three-Dimensional; Immunohistochemistry; Interneurons; Levetiracetam; Male; Memory Disorders; Nerve Tissue Proteins; Neuropeptide Y; Nootropic Agents; Perfusion; Piracetam; Rats; Rats, Long-Evans; Somatostatin | 2013 |
The Effects of Levetiracetam on Cerebrospinal Fluid and Plasma NPY and GAL, and on the Components of Stress Response System, hs-CRP, and S100B Protein in Serum of Patients with Refractory Epilepsy.
Topics: Adolescent; Adult; Aryldialkylphosphatase; C-Reactive Protein; Enzyme-Linked Immunosorbent Assay; Epilepsy; Female; Galanin; Humans; Levetiracetam; Lipoproteins, LDL; Male; Middle Aged; Neuropeptide Y; Piracetam; Quality of Life; Radioimmunoassay; S100 Calcium Binding Protein beta Subunit; Young Adult | 2015 |